Companies /Healthcare

10x Genomics Inc - Class A

NASDAQ: TXG Medical Devices
$54.99
▼ $3.20 (−5.50%) today
Markets closed · 11:06pm ET

24/7 Wall St. View

TXG at a Glance

Valuation
Market cap
$7.7B
Profitability
Revenue (TTM)
$618.6M
Profit margin
-10.8%
EPS (TTM)
$-0.52
Price
52-week range
$15 – $103
24/7 target
$78.36
Street target
$68.14
Earnings
Next report
Feb 10, 2027

Headquartered in Pleasanton, CA Fiscal year ends December NASDAQ: TXG 10xgenomics.com

About 10x Genomics

10x Genomics is a life science technology company that sells integrated research solutions for single cell and spatial biology. Its products include instruments, consumables, software and services.

Its customers are academic and translational researchers and biopharmaceutical companies. They use the company's tools to study biological systems at high resolution and scale in areas such as oncology, immunology and neuroscience.

The spatial portfolio includes Visium, Xenium and the newly launched Atera platform, which began global commercial shipments in Q3 2026. The company also launched Sentira, a cloud analysis platform. Sentira uses NVIDIA accelerated computing for spatial data processing and Anthropic's Claude for AI-driven analysis of single cell data.

Revenue comes mainly from recurring consumables, alongside instrument sales, services, and license and royalty income, including from patent litigation settlements. The United States is its largest market, followed by EMEA and Asia-Pacific, including China. Updated

Latest Activity

TXG10x Genomics
Q3 2026
EPS
-$0.15
est -$0.02-$0.13
Revenue
$151M
est $148M+1.9%

The Atera launch is behaving like a platform transition: instrument sales fell while spatial consumables climbed to $41.19 million, and management still raised full-year revenue guidance to $625 million to $635 million. Gross margin expanded to 75% from 67%, though litigation costs and other expense of $7.44 million pulled the bottom line below consensus.

Quarterly EPS — reported vs estimate

TXG Coverage

7:40pm ET
Investing

Cathie Wood’s Top Biotech Plays for February

Don’t look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns. Notably, the flagship…

Joey Frenette

Frequently Asked Questions

What does 10x Genomics do?

10x Genomics is a life science technology company that sells integrated research solutions for single cell and spatial biology. Its products include instruments, consumables, software and services.

What is the TXG stock price target?

24/7 Wall St.'s 12-month price target for TXG is $78.36, rated Buy. The Wall Street consensus target is $68.14. TXG price prediction →